[go: up one dir, main page]

SI3638243T1 - Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo - Google Patents

Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo

Info

Publication number
SI3638243T1
SI3638243T1 SI201831166T SI201831166T SI3638243T1 SI 3638243 T1 SI3638243 T1 SI 3638243T1 SI 201831166 T SI201831166 T SI 201831166T SI 201831166 T SI201831166 T SI 201831166T SI 3638243 T1 SI3638243 T1 SI 3638243T1
Authority
SI
Slovenia
Prior art keywords
anemia
methods
myeloproliferative neoplasm
treating myeloproliferative
associated myelofibrosis
Prior art date
Application number
SI201831166T
Other languages
English (en)
Inventor
Abderrahmane Laadem
Robert Gale
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64660712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3638243(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of SI3638243T1 publication Critical patent/SI3638243T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201831166T 2017-06-14 2018-06-13 Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo SI3638243T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762519725P 2017-06-14 2017-06-14
US201862679210P 2018-06-01 2018-06-01
EP18816685.4A EP3638243B1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
PCT/US2018/037213 WO2018231905A1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Publications (1)

Publication Number Publication Date
SI3638243T1 true SI3638243T1 (sl) 2025-03-31

Family

ID=64660712

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201831166T SI3638243T1 (sl) 2017-06-14 2018-06-13 Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo

Country Status (16)

Country Link
US (1) US20200101134A1 (sl)
EP (2) EP3638243B1 (sl)
JP (2) JP7496686B2 (sl)
CN (1) CN111050770A (sl)
DK (1) DK3638243T3 (sl)
ES (1) ES2991738T3 (sl)
FI (1) FI3638243T3 (sl)
HR (1) HRP20241477T1 (sl)
HU (1) HUE068733T2 (sl)
LT (1) LT3638243T (sl)
PL (1) PL3638243T3 (sl)
PT (1) PT3638243T (sl)
RS (1) RS66093B1 (sl)
SI (1) SI3638243T1 (sl)
SM (1) SMT202400437T1 (sl)
WO (1) WO2018231905A1 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
JP2018522579A (ja) 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
PL3490582T3 (pl) * 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
WO2020092523A1 (en) * 2018-10-31 2020-05-07 Celgene Corporation TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
JP2023523568A (ja) * 2020-04-13 2023-06-06 セルジーン コーポレーション ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
CA3177632A1 (en) * 2020-05-15 2021-11-18 Melih ACAR Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
JP2024532831A (ja) * 2021-08-19 2024-09-10 ケロス セラピューティクス インコーポレイテッド アクチビン受容体ｉｉ型シグナル伝達阻害剤を使用する方法
WO2025137373A1 (en) * 2023-12-19 2025-06-26 Cellarity, Inc. Disease detection systems and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
KR101882521B1 (ko) 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
EA202090053A3 (ru) * 2011-10-17 2020-06-30 Акселерон Фарма, Инк. Способы и композиции для лечения неэффективного эритропоэза
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
EP3331550B1 (en) * 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
AU2016359695A1 (en) * 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy

Also Published As

Publication number Publication date
CN111050770A (zh) 2020-04-21
ES2991738T3 (es) 2024-12-04
LT3638243T (lt) 2024-11-11
JP7496686B2 (ja) 2024-06-07
JP2024075579A (ja) 2024-06-04
HRP20241477T1 (hr) 2025-01-03
PL3638243T3 (pl) 2025-02-10
EP3638243A1 (en) 2020-04-22
FI3638243T3 (fi) 2024-10-29
US20200101134A1 (en) 2020-04-02
SMT202400437T1 (it) 2024-11-15
WO2018231905A8 (en) 2020-01-30
PT3638243T (pt) 2024-10-31
JP2020524139A (ja) 2020-08-13
EP3638243A4 (en) 2021-03-17
HUE068733T2 (hu) 2025-01-28
EP3638243B1 (en) 2024-08-07
RS66093B1 (sr) 2024-11-29
EP4454707A3 (en) 2024-12-25
DK3638243T3 (da) 2024-10-28
EP4454707A2 (en) 2024-10-30
WO2018231905A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SI3638243T1 (sl) Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo
PT3490582T (pt) Composições para utilização no tratamento da mielofibrose
IL252631A0 (en) Activin-actrii antagonists and uses for the treatment of anemia
GB201713278D0 (en) Methods and apparatus for automonous vehicle scheduling
SG10202009635XA (en) Task-resource scheduling method and apparatus
GB201616152D0 (en) Well apparatus and associated methods
SG11201610769YA (en) Interference cancellation apparatus and method
SG11201610674QA (en) Interference cancellation apparatus and method
GB201815021D0 (en) Apparatuses and methods for providing tempreture controlled portable container
SG11201707721VA (en) Massaging apparatus
GB201509230D0 (en) Vibratory finishing apparatus, fixtures and methods
GB2552997B (en) Sliding component and method
PL3288036T3 (pl) Urządzenie i związane z nim sposoby
GB201604529D0 (en) Mixing and processing apparatus
GB201608779D0 (en) Methods and compounds
GB201608776D0 (en) Methods and compounds
GB2548976B (en) Apparatus and process
GB201613244D0 (en) Powder and process
GB201613243D0 (en) Powder and process
SG11202000935SA (en) Cis-polycycloolefins and methods for forming cis-polycycloolefins
TWM532799U (en) Shaking apparatus for furniture
GB201609619D0 (en) Vibratory treatment apparatus
GB2534130B (en) Apparatus and methods
SG11201509461XA (en) Cover For Component Of Polishing Apparatus, Component Of Polishing Apparatus, And Polishing Apparatus
ZA201903032B (en) Nail plater apparatus and related methods